Cholinesterase-like organocatalysis by imidazole and imidazole-bearing molecules by Nieri, Paola et al.
1Scientific RepoRts | 7:45760 | DOI: 10.1038/srep45760
www.nature.com/scientificreports
Cholinesterase-like organocatalysis 
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Adriano Podestà2
Organocatalysis, which is mostly explored for its new potential industrial applications, also represents 
a chemical event involved in endogenous processes. In the present study, we provide the first evidence 
that imidazole and imidazole derivatives have cholinesterase-like properties since they can accelerate 
the hydrolysis of acetylthiocholine and propionylthiocholine in a concentration-dependent manner. 
The natural imidazole-containing molecules as L-histidine and histamine show a catalytic activity, 
comparable to that of imidazole itself, whereas synthetic molecules, as cimetidine and clonidine, were 
less active. In the experimental conditions used, the reaction progress curves were sigmoidal and the 
rational of such unexpected behavior as well as the mechanism of catalysis is discussed. Although 
indirectly, findings of the present study suggests that imidazolic compounds may interfere with the 
homeostasis of the cholinergic system in vivo.
Binding specificity is the cornerstone event that characterizes the vast majority of structural and kinetic properties 
of the living state of matter. Conformational flexibility and chemistry of heteroatom substituents allow enzymes 
to efficiently catalyze specific chemical reactions in a stereospecific way. Nonetheless, many non-enzymatic reac-
tions occur in living organisms including non-specific protein glycosylation1, reduction of sugars with free amino 
groups in proteins, lipids and nucleic acids2, lipid peroxidation by free radicals3, and hemoglobin degradation by 
t-butyl hydroperoxide4.
Until the discovery of organocatalysis in the late 1990s, the field of asymmetric catalysis (dedicated to the 
synthesis of chiral molecules) was dominated by the use of organometallic compounds and enzymes. Since then, 
more than one hundred of reaction types have been described in which monomeric organic molecules were able 
to promote enantioselective catalysis in vitro5–9, even in an aqueous environment10,11. This evidence suggests that, 
under appropriate circumstances, some small molecules may act as catalysts also in vivo influencing specific bio-
logical processes. Experimental confirmation of such a hypothesis may represent the rational base to synthesize 
new drug candidates12 to be used in pathological conditions characterized by the loss of endogenous enzyme 
activity.
The imidazole moiety of the amino acid histidine plays a role in the mechanism of catalysis of a number 
of hydrolytic enzymes, including trypsin, chymotrypsin, and acetylcholinesterase. The catalytic role of the imi-
dazole group linked to polymers other than proteins13 or as part of small molecules14 has been also reported. 
Imidazole may function per se as a catalyst by promoting hydrolysis of phenyl acetate15, N-acetylserinamide and 
p-nitrophenol esters16, and cyclic peptides17, or accelerating the in vitro rate of glycerolipids synthesis18 and the 
transfer of activated acyl groups19. Furthermore, several imidazole analogues or derivatives have attracted the 
interest of the scientific community for their organocatalytic properties20.
In the present study, we provide the first evidence that imidazole and other endogenous or synthetic 
imidazole-containing molecules have a concentration-dependent cholinesterase-like activity and discuss possible 
physiological and pharmacological implications.
Results
Ellman’s assay is used to estimate free thiol groups. This reaction is based on the ability of the reagent 5,5′ 
-dithiobis-(2-nitrobenzoic acid) (DTNB) to react with the thiol to give the mixed disulfide and 2-nitro-5-thiobenzoate 
(TNB). In water (at neutral and alkaline pH conditions) TNB is in its anionic yellow form TNB2−, 
1Department of Pharmacy, University of Pisa, Pisa, Italy. ͸Department of Veterinary Sciences, University of Pisa, Italy. 
Correspondence and requests for materials should be addressed to P.N. (email: paola.nieri@unipi.it)
receie: 1Ϳ Octoer ͸016
accepte: 0͸ arc ͸017
Puise: 03 pri ͸017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:45760 | DOI: 10.1038/srep45760
which is quantified by measuring the absorbance at 405 nm (Fig. 1). Ellman’s assay for assessing cholinesterase 
activity is based on the use of thioester analogs of natural enzyme substrates, i.e. acetylthiocholine (ACTh), pro-
pionylthiocholine (PTCh) or butirrylthiocholine (BTCh)21.
For the correct assessment of the catalytic activity of imidazole and imidazole derivatives, we measured the 
extent of thioester hydrolysis that spontaneously occurs when thioesters are dissolved in water. Since both elec-
trophiles and, especially, nucleophile groups (such as the N-3 Lewis base) can cleave the S–S bond acting as polar 
reagents, we also evaluated this further source of blank hydrolysis. Findings of the present study showed that, in 
mild alkaline condition (pH 7.4), 40 mM imidazole caused a slight but significant increase in TNB2− formation, 
even in the absence of thioester molecules in the solution. Results reported below were obtained by subtracting 
the absorbance due to blank hydrolysis.
Figure 2 shows the progress curves of ATCh (1 mM) hydrolysis at 37 °C and pH 7.4, in the presence of increas-
ing imidazole concentrations. Imidazole at 1.25–40 mM enhanced ATCh hydrolysis in a concentration-dependent 
manner. Progress curves are sigmoid and they represent true and continuous functions, as revealed by the super-
imposed cubic spline.
Concentration dependency and sigmoidal behavior of dose-response curves were also observed in exper-
iments performed at 1 mM imidazole (fixed concentration) in the presence of different ATCh or PTCh con-
centrations (Fig. 3a and b respectively). Apparent kcat values were 4.53·10−5 ± 9.88·10−7 sec−1 for ATCh and 
2.53·10−5 ± 4.40·10−7 sec−1 for PTCh. Plot of the apparent v0 vs. [S] is shown in panel c. Some data series were 
truncated to avoid the misleading effect caused by spontaneous hydrolysis of the thioester that increased propor-
tionally with increasing ATCh or PTCh concentrations up to the limit to hide the catalyzed reaction.
As shown in Fig. 4, imidazole catalysis was affected by the pH of the reaction mixture and catalytic efficiency 
increased as the solution became alkaline. This evidence suggested a role of the imidazole N-3 lone pair in the 
catalytic process. Such a hypothesis was further supported by data of Fig. 5 showing the trend of the hydrol-
ysis curves obtained with 1 mM ATCh at pH 7.4 in the presence of 40 mM imidazole, 4-methylimidazole or 
1-ethyl-3-methylimidazolium chloride.
While N-alkylation of imidazole led to a complete loss of catalytic activity, the presence of a C-4 methyl sub-
stituent decreases the catalytic efficiency of the imidazole ring, suggesting a possible negative mesomeric effect of 
the alkyl substituents on the resonance of the molecule. To test this hypothesis, we monitored the ATCh hydrol-
ysis in the presence of L-histidine, histamine, clonidine and cimetidine (Fig. 6). Histamine and L-histidine had 
a behaviour similar to that of imidazole, while clonidine and cimetidine showed a very low catalytic activities.
Discussion
In the present study, we demonstrate for the first time that imidazole as well as natural (i.e. histamine 
and L-histidine) and synthetic (i.e. cimetidine and clonidine) molecules containing an imidazole ring or 
imidazole-derived moieties can act as organocatalysts increasing the hydrolysis rate of ATCh and PTCh. 
Moreover, we point out some aspects on the reaction kinetics and provide evidence on the possible catalysis 
mechanism.
Figure 1. Reaction of the Ellman’s reagent (DTNB) with a thiol. 
Figure 2. Concentration dependent cholinesterase-like activity of imidazole. Progress curves of TNB2− 
formation (pH 7.4, T 37 °C) in the presence of a fixed [ATCh] (1 mM) and increasing [imidazole]. The solid line 
represents the cubic spline transform of the data series.
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Figure 3. Imidazole organocatalytic activity vs different concentrations of Acetylthiocholine (ATCh) or 
Propionylthiocholine (PTCh). Progress curves of TNB2− formation (pH 7.4, T 37 °C) in the presence of a fixed 
[imidazole] (1 mM) and increasing [ATCh] (a) or [PTCh] (b). The solid lines in panel c represents the cubic 
spline transforms of the data series. They are omitted in panel b. Linear correlations between apparent v0 and 
[ATCh] or [PTCh] are shown in panel c. See discussion for the rational of v0(app) estimation.
Figure 4. pH influence on imidazole organocatalytic activity. Progress curves of TNB2− formation at 
different pH values (T = 37 °C, 1 mM ATCh, 5 mM imidazole).
Figure 5. Comparison of 1-ethyl-3-methylimidazolium and 4-methylimidazole vs. imidazole activity. 
Progress curves of TNB2− formation (pH 7.4, T 37 °C) in the presence of 1 mM ATCh and 40 mM imidazole, 
1-ethyl-3- methylimidazolium chloride or 4-methylimidazole.
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The imidazole concentration-dependent enhancement of ATCh and PTCh hydrolyses were characterized by a 
sigmoidal behaviour. Such a kinetic profile was observed even in experiments carried out at a fixed imidazole con-
centration in the presence of the substrate at different concentrations. Noteworthy, imidazole catalysis occurred 
with a lag time of seconds or minutes from the start of the reaction and the same kinetic behavior was observed 
when ATCh was incubated in the presence of the other compounds tested (i.e., L-histidine, histamine, cimetidine 
and clonidine).
Sigmoidal behavior of progress curves are common in enzyme allosterism and in the cooperative binding of 
molecular oxygen to hemoglobins as a consequence of conformational changes of macromolecules, while it is 
uncommon for monomeric molecules. For instance, it has been described for autocatalytic events, where a prod-
uct or an intermediate can also function as a catalyst, such as the ozone hole depletion in troposphere22. Factors 
related to the conditions of the two consecutive reactions involved in Ellman’s assay might be responsible for the 
unexpected kinetic behavior observed in the present study (please refer to specific discussion in Supplementary 
info section).
In our experimental model, the apparent kcat of thioester hydrolysis in the presence of imidazole is greater for 
ATCh than PTCh, suggesting a positive mesomeric effect of the alkyl chain of the acidic moiety of the substrate 
on the electrophile carbonyl group of the thioester. This hypothesis is in agreement with previous findings on 
imidazole catalysis of other substrates13–19.
The efficiency of imidazole catalysis in ATCh hydrolysis increases as the solution becomes alkaline, suggesting 
a possible role of the nucleophile N-3 lone pair in the catalytic mechanism. Imidazole indeed is a highly polar, pla-
nar 5-membered ring aromatic compound characterized by the presence of a sextet of π -electrons. It exists in two 
equivalent tautomeric forms, protonated on each of the two nitrogen atoms, with pKa values of 14.5, for the acidic 
N-1 proton, and 6.9 for the conjugated acid of the basic site N-323. According to the Henderson-Hasselbalch equa-
tion, in diluted solutions, a ∆ pH(solution)-pKa(N-3) = 1 implies a 10:1 molar ratio between the imidazole molecules with 
N-3 atoms bearing a lone pair available to react as a Lewis base and molecules in the form of imidazolium cations.
The role of the nucleophile N-3 lone pair in the catalytic mechanism is further supported by the fact that 
N-alkylation of imidazole (as in 1-ethyl-3-methylimidazolium) led to a complete loss of activity. The methyl sub-
stituent on the imidazole C-4 position reduced catalytic activity suggesting a negative mesomeric effect of alkyl 
substituents on the aromatic cloud of the imidazole ring particularly on the ability of the N-3 lone pair to act as a 
Lewis base reactant. In line with this notion, elongation of the alkyl chain (as in L-histidine and histamine) causes 
a further decrease of the catalytic efficiency. On the other hand, adjacent substituents in the C4 and C5 positions 
(as in cimetidine) as well as the presence of C-2 substituents (as in clonidine) cause a marked reduction of cata-
lytic efficiency, most probably due to a lost of aromaticity.
Finding of the present study also suggests a potential in vivo effect of imidazole-containing molecules. 
Organocatalysis has been recognized as an innovative method for the synthesis of natural and pharmaceutical 
products24 but little attention has been paid to its potential role in the in vivo processes. The high efficiency of 
macromolecular catalysts seems indeed to rule out the possibility of molecules with low catalytic efficiency to 
affect living systems. However, it should be pointed out that the actual concentration in vivo of the product of a 
catalyzed reaction reflects the balance between the rate of its synthesis and the rate of its disruption (steady-state 
Figure 6. Cholinesterase-like activity of imidazole-bearing molecules. Progress curves of TNB2− formation 
(pH 7.4, T 37 °C) ini the presence of a fixed [ATCh] (1 mM) and increasing [L-histidine], [histamine], 
www.nature.com/scientificreports/
5Scientific RepoRts | 7:45760 | DOI: 10.1038/srep45760
condition). Therefore, even molecules with a low but persistent catalytic activity might alter this dynamic equilib-
rium and call for an homeostatic response.
The cholinergic system represents a different and even more complex extracellular condition. Beside its widely 
recognized role as a neurotransmitter of the central and peripheral nervous systems, acetylcholine (Ach) also rep-
resents a ubiquitous cell signaling molecule and an autocrine, juxtacrine and paracrine hormone. A non-neuronal 
cholinergic system has also been identified in the epithelial, endothelial and mesothelial cells, muscle fibers, 
parenchyma, and immune cells in human organisms. Ach plays a regulatory effect on many biological events 
including cell cycle, growth, survival, proliferation and differentiation, apoptosis, cell-to-cell contact, adhesion, 
organization of the cytoskeleton in cells and tissues of neuronal and non-neuronal types, cell secretion and 
resorption, trophism and even immune function and response to stress25–30.
As a consequence of this, it is not surprising that cholinergic status alterations have been found in several 
chronic diseases, drug addiction (e.g., alcohol, opiate, cocaine, ephedron, methylenedioxymethamphetamine, 
nicotine) and addiction-related serious complications, autistic spectrum disorders, malnutrition, unhealthy life 
styles (long-term high sugar and high fat intake, substance abuse) and cancer31. Noteworthy, low cholinesterase 
levels in serum and lymphocytes have been found in a considerably large number of patients with cancer, where 
low serum cholinesterase levels correlates with the extent of malignancy and histological classification31,32. Many 
identified risk factors for cancer initiation, development, and metastasis are also high-risk factors for cholinester-
ases30,32–37. On the other hand, cholinesterase activity can be injured by many physical and chemical agents such 
as radiations38, pesticides, nerve gas agents, pharmaceuticals39,40 and natural compounds41.
As for any other molecule within the body, the local steady state concentration of Ach results from the balance 
between the rate of secretion by cells and tissues and the rate of hydrolysis by cholinesterase isozymes42. The 
enzymes responsible for Ach clearance are detectable as membrane-bound molecules exposing their active site at 
the cell surface, in intracellular membranous organelles and as soluble forms in extracellular spaces, matrices and 
body fluids. Understanding better their regulation may be an important step for discovering new pharmacological 
strategies aimed at treating diseases based on defects in the cholinergic system.
Findings of the present study showing the ability of small molecules (such as histamine and histidine) to affect 
Ach metabolism provide new insights into the role of imidazole-based compounds in physiological and patho-
logical processes.
As a matter of fact, several alimentary sources of histamine have been already identified, including many 
fishery products43. Moreover, histamine is present in almost all mammalian tissues, particularly in mastocytes, 
enterochromaffin-like cells of the oxyntic mucosa of the stomach, neurons of the central nervous system and 
blood cells44. Millimolar concentrations of histamine can be reached in inflammatory districts45,46 and probably 
in the gastrointestinal tract after ingestion of histamine rich-foods or foods triggering histamine release from the 
body. Although interactions between histamine and Ach have been already described both at peripheral and cen-
tral levels47–49, findings of the present study may offer a novel point of view for the comprehension of the complex 
relationship between histaminergic and cholinergic systems. Noteworthy, while histamine metabolism leads to 
the loss of its biological activity, it does not alter the catalytic potential of its imidazole ring, at least until the com-
plete removal from the internal milieu or the cell cytoplasm. Indeed, histamine undergoes an extracellular oxida-
tive deamination of the primary amino group to imidazole acetaldehyde by diamine oxidase, or an intracellular 
methylation by histamine-N-methyltransferase, which is then oxidatively deaminated by monoamine oxidase B 
or diamine oxidase to yield N-methyl-imidazole acetaldehyde. Both aldehydes can finally be oxidized to form the 
corresponding acetates by aldehyde dehydrogenase50.
The relevance of the histamine precursor, histidine, is not restricted to the well-known role in a catalytic triad, 
such as the Ser-His-Glu in the acetylcholinesterase enzyme itself51. Histidine-containing dipeptides catalyse RNA 
formation in eutectic water11 and they are present at micromolar to millimolar concentrations in many tissues 
of vertebrates. Some of them, such as carnosine, may act as non-mast cell reservoir of histidine and histamine52. 
Noteworthy, daily intakes of histidine trough histidine rich foods, including beef, lamb, cheese, pork, chicken, 
turkey, soy, fish, nuts, seeds, eggs, beans, and whole grains, exceed the Reference Daily Intake in developed coun-
tries53. Therefore, understanding the effect on the cholinergic system induced by endogenous molecules and 
drugs containing an imidazole ring could be important also from a nutraceutical point of view.
Conclusions
In conclusion, the present study suggests that millimolar concentrations of imidazole-based monomeric catalysts 
may potentially interfere with the cholinergic system supporting the role of histidine, histidine peptides, their 
derivatives and other autacoids as organocatalysts with potential application in the pharmaceutical and nutra-
ceutical industry.
Methods
Chemicals and reagents. The following chemicals were obtained from Sigma and stored appropriately 
until use: imidazole, 4-methylimidazole, 1-ethyl-3-methylimidazolium chloride, histamine dihydrochloride 
(2-(4-Imidazolyl)ethylamine dihydrochloride), L-histidine, clonidine hydrochloride (2-(2,6-Dichloroanilino)-2-
imidazoline hydrochloride), acetylthiocholine chloride, propionylthiocholine chloride, 5,5′ -dithiobis(2-nitroben-
zoic) acid (Ellman’s Reagent, DTNB), Electrophorus Electricus acetylcholinesterase.
Cholinesterase-like activity assay. The reaction kinetics was firstly evaluated by curves obtained main-
taining constant the substrates’ concentration (1 mM) and changing the concentrations of the organocatalyst tested 
(1.25–40 mM) or maintaining constant the organocatalyst concentration (1 mM) and changing the concentrations 
of substrates (1–32 mM). DTNB concentration was set at 200 µ M (that is a quarter of the minimal substrate con-
centration used) to obtain the maximum expected absorbance for complete mixed disulfide and TNB2− formation. 
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This consideration was done assuming a TNB2− molar absorption coefficient at 405 nm of 1.37 × 104 M−1 cm−1 at 
37 °C, that is, an absorbance value well within the sensitivity range of the spectrophotometer. The same TNB2− ε 0 
was assumed in calculations. Positive control was obtained by adding acetylcholinesterase to the reaction mixture. 
Cholinesterase-like activity was tested in 96 well plates using the Ellman’s assay21, slightly modified. All reagents 
were dissolved in phosphate-pyrophosphate buffer (50 mM), prepared by titrating sodium acid pyrophosphate 
(Na2H2P2O7) with sodium orthophosphate (Na3PO4) to pH 7.4, except for assessment of the effect of pH on catal-
ysis. This was assessed in the range of 5.8–8.0 by adding 1 mM ATCh to a 50 mM buffered solution containing 
5 mM imidazole and 200 µ M DTNB.
To measure the concentration dependency of imidazole cholinesterase-like activity, serial 1:2 dilutions of 
50 µ L of 4X imidazole (i.e. 160 mM) were performed from column 12 to 1 in duplicate; the reaction mixture was 
completed by adding 50 µ L of 4X ATCh (i.e. 4 mM) and 100 µ L of 2X DTNB (i.e. 400 µ M).
The progress curves of TNB2− formation in the presence of a fixed [imidazole] and increasing [ATCh] or 
[PTCh] were obtained by serially diluting 1:2 50 µ L of 4X [ATCh] or [PTCh] (i.e. 128 mM) from column 12 to 1 
in duplicate; the reaction mixture was completed by adding 50 µ L of 4X imidazole (i.e. 4 mM) and 100 µ L of 2X 
DTNB (i.e. 400 µ M).
The pH influence on imidazole organocatalysis was assessed by mixing 50 µ L of 4X [ATCh] (i.e. 4 mM), 50 µ L 
of 4X [imidazole] (i.e. 20 mM) and 100 µ L of 2X DTNB (i.e. 400 µ M), each dissolved in the appropriate buffer (i.e. 
phosphate-pyrophosphate buffer (50 mM) titrated to different pH in the range of 5.8–8.0 with sodium orthophos-
phate and dispensed in triplicate from column 1 to 12.
Comparison of 1-ethyl-3-methylimidazolium and 4-methylimidazole vs. imidazole activity was measured by 
mixing 50 µ L of 4X [ATCh] (i.e. 4 mM), 50 µ L of 4X DTNB (i.e. 800 µ M) and 100 µ L of 2X candidate catalyst (i.e. 
80 mM) in triplicate, from column 1 to 9.
The cholinesterase-like activity of imidazole-bearing molecules was tested by serially diluting 1:2 50 µ L of 4X 
[candidate catalyst] (i.e. 160 mM) from column 12 to 1 in duplicate and adding 50 µ L of 4X ATCh (i.e. 4 mM) and 
100 µ L of 2X DTNB (i.e. 400 µ M).
Controls for blank hydrolysis were included in every assay. The spontaneous hydrolysis of choline thioesters 
in aqueous solutions was measured by avoiding the addition of catalyst in rows G and H. The additional hydrol-
ysis coming from the imidazole-induced disruption of DTNB (see results) was measured by avoiding choline 
thioester addition in rows E and F. A final volume of 200 µ L was maintained by adding the corresponding volume 
of buffer solution.
Immediately after completion of sample preparation, plates were incubated at 37 °C and briefly shaken just 
before recording their absorbance at 405 nm (due to DTNB-derived yellow product, TNB2−, Fig. 1) by Infinite 
200 PRO NanoQuant instrument (Tecan Italia Srl, Milan, Italy), 2 min after the reaction mixture set up and then 
at 15 min intervals.
The blank hydrolysis noise has been subtracted from the recorded absorbance values and data submitted to 
numerical analysis.
Statistical analysis. Data were analyzed by appropriate statistics (i.e. cubic spline interpolation, Fisher-Z 
statistics, linear and non-linear regression) by using the Prism 4.0 software (GraphPad Software, Inc., La Jolla, 
USA). P < 0.01 was adopted as limit of significance.
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